Abstract
The aim of this research was to synthesize and chemically characterize a cancer-specific 177Lu-Au-nanoradiopharmaceutical based on gold nanoparticles (NPs), the nuclear localization sequence (NLS)-Arg-Gly-Asp peptide and an aptamer (HS-pentyl-pegaptanib) to target both the α(v)β(3) integrin and the vascular endothelial growth factor (VEGF) overexpressed in the tumor neovasculature, as well as to evaluate by the tube formation assay, the nanosystem capability to inhibit angiogenesis. 177Lu-NP-RGD-NLS-Aptamer was obtained with a radiochemical purity of 99 ± 1%. Complete inhibition of tube formation (angiogenesis) was demonstrated when endothelial cells (EA.hy926), cultured in a 3D-extracellular matrix support, were treated with the developed nanosystem.
Similar content being viewed by others
References
Yook S, Cai Z, Lu Y, Winnik MA, Pignol J, Reilly RM (2015) Radiation nanomedicine for EGFR-positive breast cancer: panitumumab-modified gold nanoparticles complexed to the β-particle-emitter, (177)Lu. Mol Pharm 12:3963–3972
Ferro-Flores G, Ocampo-García BE, Santos-Cuevas CL, De Maria Ramirez F, Azorin-Vega EP, Meléndez-Alafort L (2015) Theranostic radiopharmaceuticals based on gold nanoparticles labeled with 177Lu and conjugated to peptides. Curr Radiopharm 8:150–159
Banerjee S, Pillai M, Knapp F (2015) Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 115:2934–2974
Lopes-Bastos BM, Jiang WG, Cai J (2016) Tumour-endothelial cell communications: important and indispensable mediators of tumour angiogenesis. Anticancer Res 36:1119–1126
Frezzetti D, Gallo M, Roma C, D’Alessio A, Maiello MR, Bevilacqua S, Normanno N, De Luca A (2016) Vascular endothelial growth factor regulates the secretion of different angiogenic factors in lung cancer cells. J Cell Physiol 231:1514–1521
Lin Z, Zhang Q, Luo W (2016) Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions. Eur J Pharmacol 793:76–81
Hoffmann S, He S, Jin M, Ehren M, Wiedemann P, Ryan SJ, Hinton DR (2005) A selective cyclic integrin antagonist blocks the integrin receptors αvβ3 and αvβ5 and inhibits retinal pigment epithelium cell attachment, migration and invasion. BMC Ophthalmol 5:16
Ellert-Miklaszewska A, Poleszak K, Kaminska B (2017) Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment. Future Med Chem 9:199–221
Ocampo-García BE, Santos-Cuevas CL, De León-Rodríguez LM, García-Becerra R, Ordaz-Rosado D, Luna-Guitiérrez MA, Jiménez-Mancilla NP, Romero-Piña ME, Ferro-Flores G (2013) Design and biological evaluation of 99mTc-N2S2-Tat (49–57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins. Nucl Med Biol 40:481–487
Xiang D, Shigdar S, Qiao G, Wang T, Kouzani AZ, Zhou SF, Kong L, Li Y, Pu C, Duan W (2015) Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics 5:23
Zhou G, Wilson G, Hebbard L, Duan W, Liddle C, George J, Qiao L (2016) Aptamers: a promising chemical antibody for cancer therapy. Oncotarget 7:13446
Davis GE, Senger DR (2005) Endothelial extracellular matrix, biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97:1093–1107
Shallal HM, Minn I, Banerjee SR, Lisok A, Mease RC, Pomper MG (2014) Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjugate Chem 25:393–405
Zhang J, Niu G, Lang L, Li F, Fan X, Yan X, Yao S, Yan W, Huo L, Chen L (2017) Clinical translation of a dual integrin αvβ3–and gastrin-releasing peptide receptor–targeting PET radiotracer, 68Ga-BBN-RGD. J Nucl Med 58:228–234
Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668
Morales-Avila E, Ferro-Flores G, Ocampo-García BE, De León-Rodríguez LM, Santos-Cuevas CL, García-Becerra R, Medina LA, Gómez-Oliván L (2011) Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Bioconjugate Chem 22:913–922
Luna-Gutiérrez M, Ferro-Flores G, Ocampo-García BE, Santos-Cuevas CL, Jiménez-Mancilla N, León-Rodríguez D, Azorín-Vega E, Isaac-Olivé K (2013) A therapeutic system of 177Lu-labeled gold nanoparticles-RGD internalized in breast cancer cells. J Mex Chem Soc 57:212–219
Aranda E, Owen GI (2009) A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line. Biol Res 42:377–389
Vilchis-Juárez A, Ferro-Flores G, Santos-Cuevas C, Morales-Avila E, Ocampo-García BE, Díaz-Nieto L, Luna-Gutiérrez M, Jiménez-Mancilla N, Pedraza-López M, Gómez-Oliván L (2014) Molecular targeting radiotherapy with cyclo-RGDFK (C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice. J Biomed Nanotechnol 10:393–404
Socrates G (2004) Infrared and Raman characteristic group frequencies: tables and charts. Wiley, New Jersey
Jiménez-Mancilla N, Ferro-Flores G, Santos-Cuevas C, Ocampo-García B, Luna-Gutiérrez M, Azorín-Vega E, Isaac-Olivé K, Camacho-López M, Torres-García E (2013) Multifunctional targeted therapy system based on 99mTc/177Lu-labeled gold nanoparticles-Tat (49–57)-Lys3-bombesin internalized in nuclei of prostate cancer cells. J Labelled Compd Radiopharm 56:663–671
Pan Y, Ding H, Qin L, Zhao X, Cai J, Du B (2013) Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. J Biomed Nanotechnol 9:1746–1756
Kang B, Mackey MA, El-Sayed MA (2010) Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc 132:1517–1519
Dykman LA, Khlebtsov NG (2013) Uptake of engineered gold nanoparticles into mammalian cells. Chem Rev 114:1258–1288
Zhang J, Liu B, Liu H, Zhang X, Tan W (2013) Aptamer-conjugated gold nanoparticles for bioanalysis. Nanomedicine 8:983–993
Yeom JH, Joo M, Lee B, Kim KP, Ha NC, Park Y, Bae J, Lee K (2017) Intracellular delivery of recombinant proteins via gold nanoparticle-DNA aptamer composites is independent of the protein physicochemical properties and cell type. J Ind Eng Chem 45:5–10
Goswami N, Yao Q, Luo Z, Li J, Chen T, Xie J (2016) Luminescent metal nanoclusters with aggregation-induced emission. J Phys Chem Lett 7:962–975
Acknowledgements
This study was supported by the Mexican National Council of Science and Technology (CONACYT-SEP-CB-2014-01-242443). This research was carried out as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos, CONACyT”.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
González-Ruíz, A., Ferro-Flores, G., Azorín-Vega, E. et al. Synthesis and in vitro evaluation of an antiangiogenic cancer-specific dual-targeting 177Lu-Au-nanoradiopharmaceutical. J Radioanal Nucl Chem 314, 1337–1345 (2017). https://doi.org/10.1007/s10967-017-5465-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-017-5465-x